Z-VAD(OH)-FMK，Irreversible general caspase抑制剂(ab120382)
Key features and details
- Irreversible general caspase inhibitor
- CAS Number: 220644-02-0
- Soluble in DMSO to 20 mM
- Form / State: Solid
- Source: Synthetic
概述
-
产品名称
Z-VAD(OH)-FMK，Irreversible general caspase抑制剂 -
描述
Irreversible general caspase抑制剂 -
CAS编号
220644-02-0 -
化学结构
性能
-
分子量
453.46 -
分子式
C21H28FN3O7 -
序列
VAD (Modifications: N-terminal benzyloxycarbonyl; C-terminal FMK) -
PubChem识别号
5497170 -
存放说明
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解度概述
Soluble in DMSO to 20 mM -
处理
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
FCC(=O)C(CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C -
来源
Synthetic
-
研究领域
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab120382于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度；实际最佳的稀释度/浓度应由使用者检定。
| 应用 | Ab评论 | 说明 |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| 说明 |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
图片
-
Chemical Structure - Z-VAD(OH)-FMK, Irreversible general caspase inhibitor (ab120382)2D chemical structure image of ab120382, Z-VAD(OH)-FMK, Irreversible general caspase inhibitor
-
Western blot - Z-VAD(OH)-FMK, Irreversible general caspase inhibitor (ab120382)All lanes : Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) at 1/1000 dilution
Lane 1 : Untreated L-929 (Mouse connective tissue fibroblast cells) whole cell lysate
Lane 2 : L-929 whole cell lysate treated with 20 ng/ml TNF alpha (ab9642), 100 nM Smac mimetic, and 20 µM z-VAD (ab120382) for 8 h and then harvested.
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution
Observed band size: 54 kDa why is the actual band size different from the predicted?
Exposure time: 15 secondsBlocking and dilution buffer: 5% NFDM/TBST.
-
Functional Studies - Z-VAD(OH)-FMK, Irreversible general caspase inhibitor (ab120382)Davis J et al. PLoS One. 2013; 8(12): e82053. doi: 10.1371/journal.pone.0082053 Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/ZVAD-fmk treatment does not correct muscular dystrophy in Nol3-/-Sgcd-/- mice.
A: Muscle weights normalized to tibial length of quadriceps of mice treated with or without ZVAD-fmk for 4 weeks
B: Creatine Kinase levels
C: Quantification of the time to exhaustion as assessed by involuntary treadmill running measured from vehicle or ZVAD-fmk treated WT and Nol3-/- Sgcd-/- mice
D: Histologic images taken at 100x of Masson’s trichrome stained sections of quadriceps from vehicle or ZVAD-fmk treated WT and Nol3-/-Sgcd-/- mice
Davis J et al. PLoS One. 2013; 8(12): e82053. doi: 10.1371/journal.pone.0082053
-
Immunoprecipitation - Z-VAD(OH)-FMK, Irreversible general caspase inhibitor (ab120382)MLKL (phospho S345) was immunoprecipitated from 1mg of L-929 (Mouse connective tissue fibroblast cells) whole cell lysate treated with 20 ng/ml TNF alpha (ab9642) + 100 nM Smac mimetic + 20 µM z-VAD compound (ab120382) for 8h using ab196436 at 1/150 dilution. Western blot was performed from the immunoprecipitate using ab196436 at 1/1000 dilution. Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG, was used as secondary antibody at 1/1500 dilution.
Lane 1: L-929 whole cell lysate treated with 20 ng/ml TNF alpha (ab9642) + 100 nM Smac mimetic+ 20 µM z-VAD compound (ab120382) for 8h;10 µg (Input).
Lane 2: ab196436 IP in L-929 whole cell lysate treated with 20 ng/ml TNF alpha (ab9642) + 100 nM Smac mimetic+ 20 µM z-VAD compound (ab120382) for 8h.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab196436 in L-929 whole cell lysate treated with 20 ng/ml TNF alpha (ab9642) + 100 nM Smac mimetic+ 20 µM z-VAD compound (ab120382) for 8h.Blocking and dilution buffer and concentration: 5% NFDM/TBST.
-
Western blot - Z-VAD(OH)-FMK, Irreversible general caspase inhibitor (ab120382)All lanes : Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) at 1/1000 dilution
Lane 1 : L-929 treated with 20 ng/ml TNF alpha (ab9642), 100 nM Smac mimetic, and 20 µM z-VAD (ab120382) for 8 h, whole cell lysate
Lane 2 : Mouse brain tissue lysate
Lane 3 : Mouse colon tissue lysate
Lane 4 : Mouse lung tissue lysate
Lane 5 : Mouse retina tissue lysate
Lane 6 : Mouse liver tissue lysate
Lane 7 : Raw264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Observed band size: 54 kDa why is the actual band size different from the predicted?
Exposure time: 50 secondsBlocking and diluting buffer: 5% NFDM/TBST.
MLKL pS345 is a trigger for necroptosis. It is only detectable in infection/cellular damaged (PMID:29229989) or aging tissue (PMID: 28807105) but not in normal tissues.
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
文献 (23)
ab120382 被引用在 23 文献中.
- Montinaro A et al. Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death Differ 29:492-503 (2022). PubMed: 34535764
- Kulbay M et al. Energetic metabolic reprogramming in Jurkat DFF40-deficient cancer cells. Mol Cell Biochem 477:2213-2233 (2022). PubMed: 35460011
- Tzelepi K et al. Galactose:PEGamine coated gold nanoparticles adhere to filopodia and cause extrinsic apoptosis. Nanoscale Adv 1:807-816 (2019). PubMed: 36132240
- Xiao X et al. miR-212-5p attenuates ferroptotic neuronal death after traumatic brain injury by targeting Ptgs2. Mol Brain 12:78 (2019). PubMed: 31533781
- Ding R et al. WX20120108, a novel IAP antagonist, induces tumor cell autophagy via activating ROS-FOXO pathway. Acta Pharmacol Sin N/A:N/A (2019). PubMed: 31316176